Dr. Saag has received consultant fees (less than $10,000 each) from Roche, UCB, Nitec, and Amgen and research support from Abbott, Amgen, Centecor, Roche, and Wyeth. Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Roche, Merck, Procter and Gamble, Eli Lilly, UCB, and Novartis and research support from Amgen, Eli Lilly, Merck, Novartis, Procter and Gamble, and Roche. Dr. Paulus has received consultant fees (less than $10,000 each) from Amgen, Roche and Mathematica. Dr. Chatham has received speaking fees and honoraria (less than $10,000 each) from Bristol-Myers Squibb and Amgen. Dr. Hochberg has received consultant fees (less than $10,000 each) from Amgen and Bristol-Myers Squibb. Dr. MacLean owns stock and/or holds stock options in WellPoint. Dr. Mikuls has received speaking fees (less than $10,000 each) from Genentech and Amgen and unrestricted grants from Abbott, Amgen, and Bristol-Myers Squibb. Dr. Moreland has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Roche, Bristol-Myers Squibb, Centocor, Pfizer, Amgen, Incyte, and Genentech. Dr. O'Dell has received consultant fees and speaking fees (less than $10,000) from Abbott. Dr. Turkiewicz has received consultant fees and speaking fees (less than $10,000) from Pfizer, honoraria (less than $10,000 each) from Amgen, Wyeth, and Hoffman-LaRoche, and consultant fees, speaking fees, and honoraria (more than $10,000) from Abbott. Dr. Furst has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Actelion, Amgen, Array, Biogenidec, Bristol-Myers Squibb, Centocor, Genentech, Gilead, GlaxoSmith-Kline, Encysive, Nitec, Novartis, Roche, TAP, UCB, Wyeth, and Xoma and research support from Actelion, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Novartis, Roche, and UCB.
Article first published online: 30 MAY 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis Care & Research
Volume 59, Issue 6, pages 762–784, 15 June 2008
How to Cite
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins-Melton, M., Outman, R., Allison, J. J., Almazor, M. S., Bridges, S. L., Chatham, W. W., Hochberg, M., Maclean, C., Mikuls, T., Moreland, L. W., O'dell, J., Turkiewicz, A. M. and Furst, D. E. (2008), American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis & Rheumatism, 59: 762–784. doi: 10.1002/art.23721
Members of the Core Expert Panel: Kenneth G. Saag, MD, MSc, Jeffrey R. Curtis, MD, MPH, Harold E. Paulus, MD, Jeroan J. Allison, MD, MS, Maria Suarez Almazor, MD, MPH, S. Louis Bridges, Jr., MD, PhD, W. Winn Chatham, MD, Marc Hochberg, MD, MPH, Catherine MacLean, MD, PhD, Ted Mikuls, MD, MSPH, Larry W. Moreland, MD, James O'Dell, MD, Anthony M. Turkiewicz, MD, Daniel E. Furst, MD.
Members of the Task Force Panel: Claire Bombardier, MD, MSc (University of Toronto, Toronto, Ontario, Canada), Robin K. Dore, MD (University of California, Los Angeles), Linda F. Golodner, BA (National Consumers League, Washington, DC), Sean Hennessy, PharmD, PhD (University of Pennsylvania School of Medicine, Philadelphia), Arthur F. Kavanaugh, MD (University of California, San Diego), Dinesh Khanna, MD, MSC (University of Cincinnati, Cincinnati, Ohio, current address: University of California, Los Angeles), Joel M. Kremer, MD (Albany Medical Center, Albany, NY), Amye L. Leong, MBA (US Bone and Joint Decade, North Wales, PA), Eric L. Matteson, MD, MPH (Mayo Clinic, Rochester, MN), John T. Schousboe, MD, MS (Park Nicollet Clinic, St. Louis Park, MN, and University of Minnesota, Minneapolis), Anna N. A. Tosteson, ScD (Dartmouth Medical School, Lebanon, NH), Peter Tugwell, MD (University of Ottawa, Ottawa, Ontario, Canada), Yusuf Yazici, MD (New York University Hospital for Joint Diseases, New York).
Additional members of the University of Alabama, Birmingham (UAB) and University of California, Los Angeles (UCLA) Working Groups: Timothy Beukelman, MD, Maria I. Danila, MD, MS, Jeffrey Faggard, MD, Angelo Gaffo, MD, Allyson McDonough, MD, Raj Nair, MD, Bita Shakoory, MD, Martha Verchot, MS, MLS (UAB), Paul Maranian, MS, Shruti Scott, MPH (UCLA).
Content Specific Expert Advisors: Kevin L. Winthrop, MD, MPH (tuberculosis; Oregon Health and Science University, Portland), Gregory J. Gores, MD (hepatology; Mayo Clinic, Rochester, MN), Michael Saag, MD (human immunodeficiency virus; University of Alabama, Birmingham), Paul Shekelle, MD, PhD (RAND/UCLA Appropriateness Method; University of California, Los Angeles).
The American College of Rheumatology is an independent, professional, medical, and scientific society, which does not guarantee, warrant, or endorse any commercial product or service.
- Issue published online: 30 MAY 2008
- Article first published online: 30 MAY 2008
- Manuscript Accepted: 13 MAR 2008
- Manuscript Received: 10 DEC 2007
- Agency for Healthcare Research and Quality. Grant Number: U18-H510389
- University of Alabama
- Birmingham Center for Education and Research on Therapeutics of Musculoskeletal Diseases
- American College of Rheumatology
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.